Allovir Inc
For the period ended Dec 31, 2024. Filed Mar 7, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 7, 2025
KLRS$1.87-18.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2024 | 2023 |
| Operating expenses: | ||
| Research and development | $12,340 | $133,070 |
| General and administrative | 42,916 | 48,261 |
| Restructuring costs | 10,185 | — |
| Impairment costs | — | 18,570 |
| Total operating expenses | 65,441 | 199,901 |
| Loss from operations | (65,441) | (199,901) |
| Total other income (loss), net: | ||
| Interest income | 5,486 | 5,734 |
| Other income (loss), net | 1,186 | 3,623 |
| Loss before income taxes | (58,769) | (190,544) |
| Income tax benefit | — | (126) |
| Net loss | $(58,769) | $(190,418) |
| Net loss per share — basic and diluted | $(11.73) | $(42.09) |
| Weighted-average common shares outstanding — basic and diluted | 5,008,449 | 4,524,226 |
| Comprehensive loss: | ||
| Net loss | $(58,769) | $(190,418) |
| Other comprehensive income (loss), net of tax: | ||
| Unrealized (loss) gain on available-for-sale securities | (73) | 406 |
| Total other comprehensive income (loss) | (73) | 406 |
| Comprehensive loss | $(58,842) | $(190,012) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.